Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
82
Recruiting, industry sponsors, Respiratory, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed890
82 trials
Showing 1 to 25, recently updated first.
- Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPDPivotal-lookingRecruiting
Altesa Biosciences, Inc.Industry
NCT07610395 · 180 participants (planned) · Start May 1, 2026 · Primary completion Nov 15, 2027
Drug: VPV 1000 mg; VPV 500 mg · For: Rhinovirus Infection
Sites: Mobile, Alabama; Tempe, Arizona; Inglewood, California · 46 sites in all
AeroRx Therapeutics Inc.Industry
NCT07896252 · 64 participants (planned) · Start Nov 1, 2026 · Primary completion Jun 2027
Drug: AERO-001; AERO-002 and 1 more · For: COPD; Chronic Obstructive Pulmonary Disease (COPD); Lung Disease Chronic and 1 more
Sites: London, United Kingdom; Manchester, United Kingdom
- A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07082738 · 987 participants (planned) · Start Jun 27, 2025 · Primary completion Aug 31, 2027
Drug: AZD6793 · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 369 sites in all
Oorja Bio, Inc.Industry
NCT07869147 · 95 participants (planned) · Start Nov 2026 · Primary completion Jan 2029
Drug: ORJ-001 · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Doral, Florida; DuBois, Pennsylvania
- Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Contineum TherapeuticsIndustry
NCT07284459 · 324 participants (planned) · Start Jan 8, 2026 · Primary completion May 2028
Drug: PIPE-791 Dose A; PIPE-791 Dose B and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Mar del Plata, Argentina; Quilmes, Argentina; Buenos Aires, Argentina · 113 sites in all
- A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07915791 · 279 participants (planned) · Start Oct 29, 2026 · Primary completion Mar 7, 2029
Drug: GSK3862995B; GSK5784283 and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Newport Beach, California; Miami, Florida; Derby, Kansas · 10 sites in all
AllRock Bio, Inc.Industry
NCT07175038 · 40 participants (planned) · Start Oct 1, 2025 · Primary completion Mar 2027
Drug: ROC-101 · For: Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension, Interstitial Lung Disease
Sites: Phoenix, Arizona; Rancho Cordova, California; Aurora, Colorado · 25 sites in all
- A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07822334 · 104 participants (planned) · Start Oct 28, 2026 · Primary completion Oct 11, 2028
Drug: RO7830698; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD); Healthy Participants
Sites: Wythenshawe, United Kingdom
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingRecruiting
Rein TherapeuticsIndustry
NCT06968845 · 120 participants (planned) · Start Feb 2, 2026 · Primary completion Sep 30, 2027
Drug: LTI-03; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Birmingham, Alabama; Los Angeles, California; San Diego, California · 48 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05222529 · 42 participants (planned) · Start Aug 29, 2022 · Primary completion Jul 30, 2027
Drug: Glycopyrronium bromide 25ug; Placebo and 1 more · For: Asthma
Sites: Rousse, Bulgaria; Sevlievo, Bulgaria; Sofia, Bulgaria · 23 sites in all
SpliSense Ltd.Industry
NCT06429176 · 64 participants (planned) · Start Jun 24, 2024 · Primary completion Oct 1, 2027
Drug: SPL84 · For: Cystic Fibrosis
Sites: Long Beach, California; Los Angeles, California; San Francisco, California · 27 sites in all
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07002034 · 100 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2027
Drug: RE104 for Injection · For: Adjustment Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 33 sites in all
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis BronchiectasisPivotal-lookingRecruiting
NCT07720375 · 300 participants (planned) · Start Aug 5, 2026 · Primary completion Feb 28, 2029
Drug: Galvokimig; Placebo · For: Non-cystic Fibrosis Bronchiectasis
Sites: Newport Beach, California; Brandon, Florida; Plantation, Florida · 7 sites in all
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisPivotal-lookingRecruiting
NCT07725939 · 402 participants (planned) · Start Jul 27, 2026 · Primary completion Jun 29, 2029
Drug: Galvokimig; Placebo · For: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Sites: Encino, California; Westminster, California; Miami, Florida · 26 sites in all
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06977581 · 252 participants (planned) · Start May 20, 2025 · Primary completion Mar 8, 2027
Drug: PF-07275315 · For: Asthma
Sites: Mobile, Alabama; Chandler, Arizona; Lancaster, California · 137 sites in all
- A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219173 · 531 participants (planned) · Start Oct 22, 2025 · Primary completion Apr 2028
Drug: Brenipatide; Brenipatide and 1 more · For: Asthma
Sites: Tempe, Arizona; Newport Beach, California; Northridge, California · 120 sites in all
- A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07759245 · 606 participants (planned) · Start Aug 7, 2026 · Primary completion May 2028
Drug: Brenipatide; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Newport Beach, California; San Diego, California · 127 sites in all
Connect Biopharm LLCIndustry
NCT07705737 · 40 participants (planned) · Start Aug 21, 2026 · Primary completion Dec 2026
Drug: Rademikibart · For: Asthma Acute; COPD Exacerbation Acute
Sites: Miami, Florida; St Louis, Missouri · 3 sites in all
- A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe AsthmaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07746687 · 440 participants (planned) · Start Oct 5, 2026 · Primary completion Sep 11, 2029
Drug: JNJ-95597528; Placebo · For: Asthma
Sites: Westminster, California; Boston, Massachusetts; Minneapolis, Minnesota · 19 sites in all
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseasePivotal-lookingRecruiting
Enanta Pharmaceuticals, IncIndustry
NCT07908381 · 860 participants (planned) · Start Oct 19, 2026 · Primary completion Jul 2029
Drug: zelicapavir; Placebo · For: RSV
Sites: Cape Coral, Florida; Miami, Florida; Bluffton, South Carolina · 4 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05587712 · 42 participants (planned) · Start Jan 19, 2023 · Primary completion Sep 21, 2028
Drug: Sotatercept · For: Pulmonary Arterial Hypertension
Sites: Los Angeles, California; Palo Alto, California; San Francisco, California · 35 sites in all
35Pharma Inc., a GSK companyIndustry
NCT07143448 · 90 participants (planned) · Start Aug 19, 2026 · Primary completion Mar 2028
Drug: HS235 · For: Pulmonary Arterial Hypertension
Sites: Tampa, Florida; Boston, Massachusetts; Providence, Rhode Island · 7 sites in all
- Phase 2 Study to Assess the Safety and Efficacy of ANG003Pivotal-lookingRecruiting
Anagram Therapeutics, Inc.Industry
NCT07450547 · 113 participants (planned) · Start Apr 24, 2026 · Primary completion Jul 2027
Drug: ANG003 Dose A; ANG003 Dose B and 1 more · For: Exocrine Pancreatic Insufficiency (EPI); Cystic Fibrosis (CF)
Sites: Long Beach, California; Los Angeles, California; Denver, Colorado · 28 sites in all
- Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06932263 · 540 participants (planned) · Start Mar 26, 2025 · Primary completion Jun 7, 2027
Drug: Tozorakimab; Placebo · For: Asthma
Sites: Bakersfield, California; Huntington Beach, California; La Mesa, California · 223 sites in all
- A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07652658 · 359 participants (planned) · Start Jun 11, 2026 · Primary completion Sep 18, 2028
Drug: AZD8965 low dose; AZD8965 medium dose and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Birmingham, Alabama; Phoenix, Arizona; Loma Linda, California · 198 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.